Dec 29, 2017 02:43 PM IST
Biosimilar trastuzumab, indicated for breast cancer treatment, has been co-developed by Biocon and Mylan.
- Dec 19, 2017 03:07 PM IST
The market breadth was in favour of the advances on Tuesday afternoon with 1308 stocks advancing as against 383 declines while 298 remained unchanged. On the other hand, 1831 stocks advanced and 775 stocks declined while 175 remained unchanged on the BSE.
- Dec 05, 2017 12:05 PM IST
The biologics business consists biosimilars that include monoclonal antibodies and recombinant insulins and novel biologics
- Dec 04, 2017 09:18 AM IST
Mylan and Biocon said that USFDA approved Mylan’s Ogivri, a biosimilar to Swiss biotech giant Roche's blockbuster cancer drug Herceptin, co-developed with Biocon.
- Dec 02, 2017 10:00 AM IST
The shares of Biocon opened at Rs 445, then surged 3.92 percent to touch an intra-day high of Rs 449.20 and finally settled for the day at Rs 446.55, up 3.31 percent over its previous closing price
- Nov 23, 2017 05:55 PM IST
The market size for Bevacizumab, both innovator product and biosimilars, in India is estimated at Rs 177 Crore (USD 27 million), according to IPSOS June MAT 2017 data.
- Nov 23, 2017 01:39 PM IST
The biosimilar product will be used for the treatment of patients with metastatic colorectal cancer and other types of lung, kidney, cervical, ovarian and brain cancers in India, Biocon said in a filing to the BSE.
- Nov 20, 2017 01:22 PM IST
The company has been told that the May inspection has been closed and they can carry on CAPA implementation, said Kiran Mazumdar Shaw, CMD, Biocon.
- Nov 20, 2017 10:22 AM IST
"The US Food and Drug Administration (USFDA) has issued an Establishment Inspection Report in relation to the cGMP (current good manufacturing practice) inspection of its aseptic drug product facility that was audited between May 25 -June 3, 2017," Biocon said in a BSE filing.
- Nov 14, 2017 10:40 AM IST
The company today said the expanded scope of partnership also includes addition of a new facility and ramping up the team of scientists working for it.
- Nov 09, 2017 11:17 AM IST
Axis Direct is bullish on Biocon has recommended buy rating on the stock with a target price of Rs 410 in its research report dated November 02, 2017.
- Oct 27, 2017 12:53 PM IST
In an interview to CNBC-TV18, Kiran Mazumdar Shaw, Chairperson & MD of Biocon spoke about the results and her outlook for the company.
- Oct 13, 2017 05:40 PM IST
Net Sales are expected to increase by 8.4 percent Y-o-Y (up 9.1 percent Q-o-Q) to Rs. 1018.9 crore, according to Kotak.
- Oct 10, 2017 03:56 PM IST
Sandeep Wagle of powermywealth.com suggests buying Hexaware Technologies and Biocon.
- Oct 10, 2017 03:01 PM IST
Prakash Gaba of prakashgaba.com is of the view that one can go long in Apollo Hospitals and Biocon.
- Oct 10, 2017 02:20 PM IST
This product is a part of the biosimilars portfolio being developed jointly by Biocon and Mylan. "The US Food and Drug Administration has issued a CRL for Mylan's Biologics License Application (BLA) for MYL-1401H, a proposed biosimilar Pegfilgrastim", Biocon spokesperson said in a statement.
- Oct 10, 2017 11:46 AM IST
The company, however said it does not expect this CRL to impact the commercial launch timing of biosimilar Pegfilgrastim in the US. This product is a part of the biosimilars portfolio being developed jointly by Biocon and Mylan.
- Oct 10, 2017 11:13 AM IST
Ashwani Gujral of ashwanigujral.com recommends buying Prestige Estates, MOIL, TVS Motor, Kotak Mahindra Bank and Bata India.
- Oct 10, 2017 11:04 AM IST
In an interview to CNBC-TV18, Vishal Manchanda, Pharma Analyst at Nirmal Bang Institutional Equities shared his views and readings on the news as well as on Biocon stock.
- Oct 10, 2017 10:36 AM IST
Siyaram Silk, HEG Limited, Jindal Worldwide, Goa Carbon and VIP Industries were the stocks that hit 52-week high in the Nifty while within the BSE Index, stocks like Gillette India, Kotak Mahindra Bank, Bharat Financial, Bata India, Tata Steel, TVS Motor and TVS Electronics hit 52-week high in today's trade.
- Oct 09, 2017 03:21 PM IST
Biocon is under pressure today. The target action date for cancer drug pegfilgrastim is today.
- Oct 06, 2017 01:58 PM IST
The chairperson and managing director of Bengaluru- headquartered Biocon Ltd, with a fortune of USD 2.16 billion, was placed at the 72nd position on Forbes magazine's annual 'India Rich List 2017'.
- Sep 21, 2017 02:27 PM IST
Sudarshan Sukhani of s2analytics.com is of the view that one can buy Biocon and Bajaj Auto and can sell Indo Count Industries.
- Sep 21, 2017 11:56 AM IST
Divis Laboratories, Dr Reddy's Laboratories, Aurobindo Pharma, Biocon and Lupin will get astrological support, says Satish Gupta of astrostocktips,
- Sep 19, 2017 10:07 AM IST
VK Sharma, Head - PCG and Capital Market Strategy at HDFC Securities suggests buying Titan Company, Eicher Motors, Biocon, Dr Reddy's Labs and IDFC.